BTL Vanquish receives FDA clearance for circumferential reduction

03 Jul 2015

Global device manufacturer BTL Aesthetics has announced that its Vanquish device has been cleared by the Food and Drug Administration (FDA) for non-surgical circumferential reduction of the abdomen.

BTL Vanquish receives FDA clearance for circumferential reduction

Of the announcement, Dr David McDaniel, dermatologist and investigator of high-tech devices for non-invasive body contouring, said, “FDA clearance of Vanquish is a significant step forward in providing the newest treatment option for body slimming and shaping.”

The system, which has been previously FDA cleared for deep tissue heating, uses a panel array that emits selective radio frequency energy with a larger spot size to treat the core in one application. The high-frequency energy field created by the technology aims to target the thermal effects into the fat layer for contouring and waistline reduction, while protecting the surrounding tissue.

Andrea Morrison, BTL’s director of clinical development, said, “FDA clearance of BTL Vanquish marks a defining moment in our journey to provide physicians and their patients an elegant treatment option to target fat cells and bring about a reduction in the waist circumference.”

Comments

Log-in to post a comment